Welch & Forbes LLC Has $8.43 Million Position in Bristol-Myers Squibb Co (BMY)

Welch & Forbes LLC lowered its position in Bristol-Myers Squibb Co (NYSE:BMY) by 17.9% in the first quarter, HoldingsChannel.com reports. The firm owned 176,668 shares of the biopharmaceutical company’s stock after selling 38,632 shares during the period. Welch & Forbes LLC’s holdings in Bristol-Myers Squibb were worth $8,429,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in BMY. Norges Bank purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $797,038,000. Oregon Public Employees Retirement Fund grew its holdings in shares of Bristol-Myers Squibb by 2,326.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,230,504 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 8,850,072 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd grew its holdings in shares of Bristol-Myers Squibb by 6,090.3% in the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 4,130,436 shares of the biopharmaceutical company’s stock valued at $214,700,000 after purchasing an additional 4,063,712 shares during the period. Prudential Financial Inc. grew its holdings in shares of Bristol-Myers Squibb by 90.9% in the fourth quarter. Prudential Financial Inc. now owns 4,967,474 shares of the biopharmaceutical company’s stock valued at $257,891,000 after purchasing an additional 2,365,961 shares during the period. Finally, Ronna Sue Cohen grew its holdings in shares of Bristol-Myers Squibb by 4,702.2% in the first quarter. Ronna Sue Cohen now owns 1,518,227 shares of the biopharmaceutical company’s stock valued at $1,518,000 after purchasing an additional 1,486,612 shares during the period. 76.62% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts recently issued reports on the stock. Argus lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective for the company. in a report on Monday, May 20th. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a report on Tuesday, May 7th. ValuEngine raised shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 4th. JPMorgan Chase & Co. initiated coverage on shares of Bristol-Myers Squibb in a research note on Friday, May 3rd. They set an “overweight” rating and a $62.00 target price for the company. Finally, Barclays raised shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $53.00 to $55.00 in a research note on Friday, May 3rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $56.88.

In other news, insider Karen Murphy Santiago sold 3,065 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the sale, the insider now owns 3,066 shares of the company’s stock, valued at $145,818.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Theodore R. Samuels II purchased 5,000 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, May 16th. The shares were acquired at an average cost of $47.29 per share, for a total transaction of $236,450.00. Following the transaction, the director now directly owns 27,000 shares of the company’s stock, valued at approximately $1,276,830. The disclosure for this purchase can be found here. Company insiders own 0.12% of the company’s stock.

BMY stock traded down $0.49 during mid-day trading on Friday, hitting $46.81. 9,468,896 shares of the company were exchanged, compared to its average volume of 14,260,501. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.93 and a quick ratio of 1.79. The firm has a market cap of $76.57 billion, a PE ratio of 11.76, a price-to-earnings-growth ratio of 2.22 and a beta of 0.77. Bristol-Myers Squibb Co has a 12-month low of $44.30 and a 12-month high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.09 by $0.01. The company had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. Bristol-Myers Squibb’s revenue was up 14.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.94 earnings per share. Sell-side analysts anticipate that Bristol-Myers Squibb Co will post 4.18 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were paid a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a yield of 3.50%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.thestockobserver.com/2019/05/25/welch-forbes-llc-has-8-43-million-position-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: Gap Down Stocks

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.